ALEC
$2.23
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States.
Recent News
Wall Street Turns Bullish on HIMS, TDOC and ALEC as Partnerships Reshape Risk Profiles
Three health-technology names are drawing fresh analyst attention this week as strategic partnerships and business pivots reframe the risk-reward calculus for each. Hims & Hers Health (NYSE:HIMS) received two separate upgrades after resolving its legal dispute with Novo Nordisk (NYSE:NVO) through a distribution partnership. Teladoc Health (NYSE:TDOC) earned a Buy from Deutsche Bank on valuation ... Wall Street Turns Bullish on HIMS, TDOC and ALEC as Partnerships Reshape Risk Profiles
Alector (ALEC)'s Technical Outlook is Bright After Key Golden Cross
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
How The Alector (ALEC) Story Is Shifting As Analyst Targets And Sector Views Evolve
Alector’s story on Wall Street has shifted slightly, with one key analyst moving the price target from US$0.75 to US$0.90 while the fair value estimate remains at $2.10. That tweak lines up with fresh commentary that links Alector to a wider group of U.S. small and mid cap biotechs that some expect could gradually move toward funding themselves as big pharma peers approach a patent cliff. As you read on, you will see how this updated target fits into the evolving analyst narrative and what it...
Alector Showcases ABC Brain-Delivery Platform, AL137 and AL050 Updates at TD Cowen Conference
Alector (NASDAQ:ALEC) used a presentation at the 46th Annual TD Cowen Healthcare Conference to highlight progress on its Alector Brain Carrier (ABC) platform, which is designed to deliver multiple therapeutic “cargos” across the blood-brain barrier using the transferrin receptor (TfR). Eric Brown, h
Alector (ALEC) Reports Q4 Loss, Beats Revenue Estimates
Alector (ALEC) delivered earnings and revenue surprises of +13.71% and +103.43%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?